R-006
Risperidone solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
About This Item
Empfohlene Produkte
Qualität
certified reference material
Form
liquid
Leistungsmerkmale
Snap-N-Spike®/Snap-N-Shoot®
Verpackung
ampule of 1 mL
Hersteller/Markenname
Cerilliant®
Konzentration
1.0 mg/mL in methanol
Methode(n)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
Anwendung(en)
clinical testing
Format
single component solution
Lagertemp.
−20°C
SMILES String
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1
InChI
1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
InChIKey
RAPZEAPATHNIPO-UHFFFAOYSA-N
Angaben zum Gen
human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)
Allgemeine Beschreibung
Anwendung
- Vascular Syndromes and Neuroleptic Therapy: RisperiDonesolution has been investigated for its role in inducing severe vascular occlusion-like syndromes in rat models. Research highlights its potential implications for understanding drug-induced vascular problems and testing therapies like BPC 157, a gastric pentadecapeptide with promising therapeutic effects (Strbe et al., 2023).
- UHPLC Method Development: RisperiDoneis a focal point in the development of an advanced UHPLC method using the "Method Operable Design Region" (MODR) approach. This method is designed for the assay and purity determination of risperiDonein various formulations, crucial for maintaining stringent quality controls in pharmaceutical manufacturing (Pawar et al., 2022).
- Optimizing Antipsychotic Dose Regimens: Research incorporates risperiDoneto explore Maximum A Posteriori (MAP) Bayesian modelling, merging drug plasma concentrations and dopamine receptor occupancy. This approach aims to customize antipsychotic dosing to enhance therapeutic outcomes in individual patients, emphasizing personalized medicine in psychiatry (Ismail et al., 2022).
- Antioxidant-mediated Drug Degradation: Studies on risperiDonealso cover the formulation aspects, such as its inclusion in poly(ethylene carbonate) systems to control drug degradation through antioxidant mediation. This research is pivotal in developing sustained-release formulations that enhance drug stability and efficacy (Bohr et al., 2020).
- Patient-reported Outcomes in Schizophrenia Treatment: RisperiDonesolution is studied for its effectiveness in treating schizophrenia, particularly assessing patient-reported outcomes in long-term therapy settings. This research helps gauge patient satisfaction and treatment efficacy, which is essential for optimizing mental health therapies (Dhanda et al., 2019).
Rechtliche Hinweise
Ähnliches Produkt
Signalwort
Danger
H-Sätze
Gefahreneinstufungen
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Zielorgane
Eyes,Central nervous system
Lagerklassenschlüssel
3 - Flammable liquids
WGK
WGK 2
Flammpunkt (°F)
49.5 °F - closed cup
Flammpunkt (°C)
9.7 °C - closed cup
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.